How to administer rhIL - 11 injection correctly?

Recombinant human interleukin-11 (rhIL-11) injection is a crucial therapeutic agent used in the medical field, particularly in the management of thrombocytopenia following certain chemotherapy regimens. As a reliable supplier of rhIL-11 injection, we understand the importance of its correct administration to ensure its effectiveness and patient safety. In this blog, we will delve into the details of how to administer rhIL-11 injection correctly.

Understanding rhIL-11 Injection

Before we proceed to the administration process, it is essential to have a basic understanding of what rhIL-11 injection is and its therapeutic purpose. RhIL-11 is a cytokine that stimulates the production of platelets in the bone marrow. It is used to prevent severe thrombocytopenia and reduce the need for platelet transfusions in patients undergoing non - myeloid chemotherapy.

Pre - injection Preparations

1. Storage and Handling

Proper storage is vital to maintain the integrity and efficacy of rhIL-11 injection. The injection should be stored in a refrigerator at 2 - 8°C (36 - 46°F). Do not freeze the product, as freezing can damage the protein structure of rhIL-11. Before administration, inspect the vial for any signs of damage, such as cracks or leaks. Also, check the expiration date on the vial. If the vial is damaged or the product has expired, do not use it.

2. Gathering Supplies

You will need the following supplies for the injection:

• RhIL-11 injection vial
• Sterile syringe and needle of appropriate size (usually a 25 - 27 gauge, 5/8 - inch needle for subcutaneous injection)
• Alcohol swabs
• Cotton balls or gauze pads
• Sharps container for safe disposal of used needles

3. Patient Assessment

Before administering the injection, assess the patient's medical history, including any allergies to rhIL-11 or other medications. Check the patient's platelet count, as the decision to administer rhIL-11 may be based on the platelet level. Also, evaluate the patient's general condition, such as vital signs and any signs of infection or other comorbidities.

Administration Procedure

1. Wash Hands

Thoroughly wash your hands with soap and water for at least 20 seconds. Dry your hands with a clean towel or paper towel. This step helps prevent the introduction of bacteria into the injection site.

2. Prepare the Injection

• Remove the rhIL-11 injection vial from the refrigerator and allow it to reach room temperature. This usually takes about 30 minutes.
• Clean the rubber stopper of the vial with an alcohol swab. Let it dry for a few seconds.
• Draw air into the syringe equal to the volume of the rhIL-11 injection you need to withdraw.
• Insert the needle through the rubber stopper of the vial and inject the air into the vial.
• Invert the vial and withdraw the appropriate volume of rhIL-11 injection into the syringe. Make sure there are no air bubbles in the syringe. If there are air bubbles, gently tap the syringe to move the bubbles to the top and then push the plunger slightly to expel the air.

3. Select the Injection Site

RhIL-11 injection is typically administered subcutaneously. Common injection sites include the abdomen (at least 2 inches away from the navel), the outer aspect of the upper arms, and the front of the thighs. Rotate the injection sites with each dose to prevent skin irritation and tissue damage.

4. Clean the Injection Site

Use an alcohol swab to clean the selected injection site in a circular motion. Start from the center of the site and move outward. Let the alcohol dry completely before proceeding with the injection.

5. Administer the Injection

• Pinch the skin at the injection site to form a small fold.
• Insert the needle at a 45 - 90 degree angle into the subcutaneous tissue. The angle depends on the patient's body fat. For patients with less body fat, a 45 - degree angle may be more appropriate, while for patients with more body fat, a 90 - degree angle can be used.
• Slowly inject the rhIL-11 solution into the subcutaneous tissue by pushing the plunger of the syringe.
• After injecting the entire dose, withdraw the needle quickly and apply gentle pressure to the injection site with a cotton ball or gauze pad. Do not massage the injection site, as this may cause bruising.

6. Dispose of the Needle and Syringe

Immediately after use, place the used needle and syringe in a sharps container. Do not recap the needle, as this can increase the risk of needlestick injuries.

Post - injection Care

1. Observe the Patient

After administering the rhIL-11 injection, observe the patient for at least 15 - 30 minutes for any signs of an allergic reaction, such as itching, swelling, difficulty breathing, or dizziness. Also, monitor the patient's vital signs, including blood pressure, heart rate, and respiratory rate.

2. Monitor Platelet Count

Regularly monitor the patient's platelet count to assess the response to rhIL-11 therapy. The platelet count usually starts to increase within 5 - 9 days after the start of treatment. The treatment may be continued until the platelet count reaches an acceptable level.

3. Document the Administration

Record the date, time, dose, injection site, and any patient - related observations in the patient's medical record. This documentation is important for continuity of care and for evaluating the patient's treatment progress.

Potential Side Effects and Precautions

1. Side Effects

Common side effects of rhIL-11 injection include fluid retention, which can lead to peripheral edema, shortness of breath, and rapid weight gain. Other side effects may include nausea, vomiting, diarrhea, and headache. In rare cases, severe allergic reactions may occur.

2. Precautions

• RhIL-11 injection should be used with caution in patients with a history of heart failure or other cardiovascular diseases, as fluid retention can exacerbate these conditions.
• Do not administer rhIL-11 injection to patients who are allergic to rhIL-11 or any of its components.
• Inform the patient about the potential side effects of rhIL-11 injection and advise them to report any unusual symptoms immediately.

Related Products

In addition to rhIL-11 injection, we also supply other important medications in the oncology field. For example, Fulvestrant Injection– An Anti-cancer Drug,CAS No.: 129453-61-8, Bulk and Injection (PFS): 250mg in 5ml is an anti - cancer drug used in the treatment of hormone - receptor - positive metastatic breast cancer. Another product is Palonosetron Hydrochloride Injection– Anti-emesis After Chemotherapy Or Radiotherapy, CAS No.: 135729-62-3, Palonosetron Hydrochloride Injection 0.25mg/5ml, 0.075mg/1.5ml, which is used to prevent nausea and vomiting after chemotherapy or radiotherapy. You can also check out Fulvestrant– An Anti-cancer Drug ,CAS No.: 129453-61-8 for more information.

Conclusion

Correct administration of rhIL-11 injection is crucial for its therapeutic efficacy and patient safety. By following the steps outlined in this blog, healthcare providers can ensure that the injection is administered safely and effectively. As a reliable supplier of rhIL-11 injection, we are committed to providing high - quality products and supporting healthcare professionals in the proper use of our medications. If you are interested in purchasing rhIL-11 injection or our other products, please contact us for more details and to initiate a procurement discussion.

References

• National Comprehensive Cancer Network (NCCN) Guidelines for Hematopoietic Growth Factors.
• Package insert of rhIL-11 injection.
• Clinical trials and research studies on the use of rhIL-11 in the management of thrombocytopenia.